DK1071804T3 - Anvendelse af triplex-struktur-dna-sekvenser til overførsel af nukleotidsekvenser - Google Patents

Anvendelse af triplex-struktur-dna-sekvenser til overførsel af nukleotidsekvenser

Info

Publication number: DK1071804T3
Authority: DK; Denmark
Prior art keywords: retroviral; recombinant; regulators; particles; sequence
Prior art date: 1998-04-24

Application number

DK99915829.8T

Other languages

English (en)

Inventor

Pierre Charneau

Veronique Zennou

Hueseyin Firat

Original Assignee

Pasteur Institut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-24

Filing date

1999-04-23

Publication date

2012-07-02

1999-04-23 Application filed by Pasteur Institut filed Critical Pasteur Institut

2012-07-02 Application granted granted Critical

2012-07-02 Publication of DK1071804T3 publication Critical patent/DK1071804T3/da

Links

108091028043 Nucleic acid sequence Proteins 0.000 title 2
230000001177 retroviral effect Effects 0.000 abstract 6
239000002245 particle Substances 0.000 abstract 3
239000002157 polynucleotide Substances 0.000 abstract 3
102000040430 polynucleotide Human genes 0.000 abstract 3
108091033319 polynucleotide Proteins 0.000 abstract 3
238000010839 reverse transcription Methods 0.000 abstract 3
108700019146 Transgenes Proteins 0.000 abstract 2
239000002773 nucleotide Substances 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
101710091045 Envelope protein Proteins 0.000 abstract 1
101710177291 Gag polyprotein Proteins 0.000 abstract 1
101710125418 Major capsid protein Proteins 0.000 abstract 1
101710188315 Protein X Proteins 0.000 abstract 1
102100021696 Syncytin-1 Human genes 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
229960001438 immunostimulant agent Drugs 0.000 abstract 1
239000003022 immunostimulating agent Substances 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
230000000977 initiatory effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
238000004806 packaging method and process Methods 0.000 abstract 1
108010089520 pol Gene Products Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK99915829.8T 1998-04-24 1999-04-23 Anvendelse af triplex-struktur-dna-sekvenser til overførsel af nukleotidsekvenser DK1071804T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9805197A FR2777909B1 (fr)	1998-04-24	1998-04-24	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
PCT/FR1999/000974 WO1999055892A1 (fr)	1998-04-24	1999-04-23	Utilisation de sequences d'adn de structure triplex pour le transfert de sequences nucleotidiques

Publications (1)

Publication Number	Publication Date
DK1071804T3 true DK1071804T3 (da)	2012-07-02

Family

ID=9525665

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99915829.8T DK1071804T3 (da)	1998-04-24	1999-04-23	Anvendelse af triplex-struktur-dna-sekvenser til overførsel af nukleotidsekvenser

Country Status (12)

Country	Link
US (6)	US6682907B1 (da)
EP (2)	EP2292778B1 (da)
JP (1)	JP4571306B2 (da)
AT (1)	ATE553205T1 (da)
AU (1)	AU3427299A (da)
CA (1)	CA2326719C (da)
CY (1)	CY1112985T1 (da)
DK (1)	DK1071804T3 (da)
ES (2)	ES2607484T3 (da)
FR (1)	FR2777909B1 (da)
PT (1)	PT1071804E (da)
WO (1)	WO1999055892A1 (da)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2777909B1 (fr) *	1998-04-24	2002-08-02	Pasteur Institut	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
EP2169073B1 (en) *	1999-10-11	2013-11-13	Institut Pasteur	Vector for the preparation of immunotherapeutical compositions
WO2001027304A2 (en)	1999-10-12	2001-04-19	Institut Pasteur	Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7419829B2 (en) *	2000-10-06	2008-09-02	Oxford Biomedica (Uk) Limited	Vector system
US7575924B2 (en)	2000-11-13	2009-08-18	Research Development Foundation	Methods and compositions relating to improved lentiviral vectors and their applications
WO2003012054A2 (en) *	2001-08-02	2003-02-13	Institut Clayton De La Recherche	Methods and compositions relating to improved lentiviral vector production systems
CA2462628C (en)	2001-10-02	2019-08-20	Institut Clayton De La Recherche	Restricted expression lentiviral vectors
US20030194392A1 (en) *	2002-04-10	2003-10-16	Pierre Charneau	Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
WO2004036188A2 (en) *	2002-10-18	2004-04-29	Cylene Pharmaceuticals, Inc.	Processes for identifying quadruplex-targeted antiviral molecules
FR2870126B1 (fr) *	2004-05-17	2009-07-17	Pasteur Institut	Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en)	2005-05-16	2012-07-17	Institut Pasteur	Lentiviral vector-based vaccine
EP1748067A1 (en)	2005-07-29	2007-01-31	Institut Pasteur	Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
EP3293266B1 (en)	2007-05-04	2025-12-24	University Health Network	Il-12 immunotherapy for cancer
JP2011517409A (ja) *	2008-03-28	2011-06-09	バイレクシスコーポレイション	レンチウイルスベースの免疫原性ベクター
US8323891B2 (en) *	2008-08-01	2012-12-04	Claflin University	miRNA triplex formations for the downregulation of viral replication
EP2385107B1 (en)	2010-05-03	2016-08-24	Institut Pasteur	Lentiviral vector based immunological compounds against malaria
EP2666477A1 (en)	2012-05-23	2013-11-27	Theravectys	Lentiviral vectors containing an MHC class I promoter
EP2643343A1 (en)	2010-11-26	2013-10-02	Institut Pasteur	Identification of a human gyrovirus and applications.
CN105821078A (zh)	2010-12-09	2016-08-03	巴斯德研究所	用于获得高产量重组蛋白表达的基于mgmt的方法
AU2012267512B2 (en)	2011-06-10	2014-11-20	Bluebird Bio, Inc.	Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
SMT201800284T1 (it)	2011-06-10	2018-07-17	Univ Oregon Health & Science	Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en)	2011-09-12	2013-04-03	International AIDS Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
JP6066356B2 (ja)	2011-09-23	2017-01-25	ブルーバードバイオ，インコーポレイテッド	改善された遺伝子治療方法
EP3269802B1 (en)	2011-09-30	2019-10-23	Bluebird Bio, Inc.	Compounds for improved viral transduction
EP2586461A1 (en)	2011-10-27	2013-05-01	Christopher L. Parks	Viral particles derived from an enveloped virus
EP2788477A2 (en)	2011-12-07	2014-10-15	Institut Pasteur	Identification of a swine parecho-like virus and applications
JP6215223B2 (ja)	2011-12-09	2017-10-18	アンスティテュ・パストゥール	マルチプレックス免疫スクリーニングアッセイ
US9347065B2 (en)	2012-03-29	2016-05-24	International Aids Vaccine Initiative	Methods to improve vector expression and genetic stability
US20150182617A1 (en)	2012-07-25	2015-07-02	Theravectys	Glycoproteins for pseudotyping lentivectors
AU2013352156B2 (en)	2012-11-27	2018-12-06	Children's Medical Center Corporation	Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
CA2907397C (en)	2013-03-15	2022-11-22	Anthrogenesis Corporation	Modified t lymphocytes
EP2878667A1 (en)	2013-11-29	2015-06-03	Institut Pasteur	TAL effector means useful for partial or full deletion of DNA tandem repeats
EP3738597A1 (en)	2014-04-25	2020-11-18	Bluebird Bio, Inc.	Improved methods for manufacturing adoptive cell therapies
IL296691B2 (en)	2014-04-25	2023-11-01	2Seventy Bio Inc	MND promoter chimeric antigen receptors
ES2744186T3 (es)	2014-04-25	2020-02-24	Childrens Medical Center	Composiciones y métodos para tratar las hemoglobinopatías
CN106793780B (zh)	2014-06-06	2020-05-26	蓝鸟生物公司	改善的t细胞组合物
MX2017001079A (es)	2014-07-24	2017-09-12	Bluebird Bio Inc	Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP3031923A1 (en)	2014-12-11	2016-06-15	Institut Pasteur	Lentiviral vector-based japanese encephalitis immunogenic composition
EP3971210A1 (en)	2014-12-12	2022-03-23	2seventy bio, Inc.	Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
MA41346A (fr)	2015-01-12	2017-11-21	Juno Therapeutics Inc	Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016128549A1 (en)	2015-02-13	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
ES2835861T5 (en)	2015-05-08	2025-02-18	Childrens Medical Ct Corp	Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction
ES2911015T3 (es)	2015-08-31	2022-05-17	Helixmith Co Ltd	Receptores quiméricos de antígeno anti-sialil Tn
WO2017099712A1 (en)	2015-12-07	2017-06-15	Bluebird Bio, Inc.	Improved t cell compositions
WO2017134265A1 (en)	2016-02-05	2017-08-10	Institut Pasteur	Use of inhibitors of adam12 as adjuvants in tumor therapies
RU2021103425A (ru)	2016-02-12	2021-02-25	Блубёрд Био, Инк.	Композиции, повышающие число копий вектора (чкв), и способы их применения
EP3413896B1 (en)	2016-02-12	2021-03-17	Bluebird Bio, Inc.	Vcn enhancer compositions and methods of using the same
EP3211003A1 (en)	2016-02-24	2017-08-30	Institut Pasteur	T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
EP3443001B1 (en)	2016-04-11	2025-04-30	Obsidian Therapeutics, Inc.	REGULATED BIOCIRCUIT SYSTEMS
WO2017180993A1 (en)	2016-04-14	2017-10-19	Bluebird Bio, Inc.	Salvage chimeric antigen receptor systems
MX2018013352A (es)	2016-05-03	2019-08-01	Univ Wayne State	Metodo para mejorar suministro de genes mediado por virus en el ojo usando inhibidores de proteosoma.
WO2018035141A1 (en)	2016-08-16	2018-02-22	Bluebird Bio, Inc.	Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use
CA3034782A1 (en)	2016-08-23	2018-03-01	Bluebird Bio, Inc.	Tim3 homing endonuclease variants, compositions, and methods of use
BR112019004629A2 (pt)	2016-09-08	2019-10-01	Bluebird Bio, Inc.	variantes de endonuclease de homing pd-1, composições e métodos de uso
MA46543A (fr)	2016-10-17	2019-08-21	Bluebird Bio Inc	Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
KR20240005168A (ko)	2016-11-04	2024-01-11	2세븐티 바이오, 인코포레이티드	항-bcma car t 세포 조성물
DK3541833T5 (da)	2016-11-17	2024-09-02	2Seventy Bio Inc	TGFß signalkonverter
EP3357506A1 (en)	2017-02-02	2018-08-08	Institut Pasteur	Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
EP3357504A1 (en)	2017-02-02	2018-08-08	Institut Pasteur	Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
US10675328B2 (en)	2017-02-14	2020-06-09	Children's Hospital Medical Center	Compositions and methods for treatment of Gcase related disease states
AU2018221730B2 (en)	2017-02-15	2024-06-20	Novo Nordisk A/S	Donor repair templates multiplex genome editing
US11261441B2 (en)	2017-03-29	2022-03-01	Bluebird Bio, Inc.	Vectors and compositions for treating hemoglobinopathies
US11788087B2 (en)	2017-05-25	2023-10-17	The Children's Medical Center Corporation	BCL11A guide delivery
EP3630962A4 (en)	2017-05-25	2021-01-20	Bluebird Bio, Inc.	Cblb endonuclease variants, compositions, and methods of use
WO2019070974A1 (en)	2017-10-04	2019-04-11	Bluebird Bio, Inc.	PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
US12522811B2 (en)	2018-05-01	2026-01-13	The Children's Medical Center Corporation	Enhanced BCL11A RNP / CRISPR delivery and editing using a 3XNLS-CAS9
WO2019213013A1 (en)	2018-05-02	2019-11-07	The Children's Medical Center Corporation	Improved bcl11a micrornas for treating hemoglobinopathies
MX2020012295A (es)	2018-05-15	2021-03-31	Flagship Pioneering Innovations V Inc	Composiciones de fusosoma y usos de estas.
DK3806903T5 (da)	2018-06-14	2024-08-19	2Seventy Bio Inc	Cd79a kimæriske antigenreceptorer
WO2020014209A1 (en)	2018-07-09	2020-01-16	Flagship Pioneering Innovations V, Inc.	Fusosome compositions and uses thereof
CN112689516A (zh)	2018-07-11	2021-04-20	细胞基因公司	抗bcma嵌合抗原受体的用途
WO2020072059A1 (en)	2018-10-04	2020-04-09	Bluebird Bio, Inc.	Cblb endonuclease variants, compositions, and methods of use
CA3120082A1 (en)	2018-11-14	2020-05-22	Flagship Pioneering Innovations V, Inc.	Fusosome compositions for cns delivery
WO2020102503A2 (en)	2018-11-14	2020-05-22	Flagship Pioneering Innovations V, Inc.	Fusosome compositions for t cell delivery
WO2020102485A1 (en)	2018-11-14	2020-05-22	Flagship Pioneering Innovations V, Inc.	Fusosome compositions for hematopoietic stem cell delivery
US12404500B2 (en)	2018-12-10	2025-09-02	Novo Nordisk A/S	Homing endonuclease variants
AU2019395334B2 (en)	2018-12-10	2026-04-23	Regeneron Pharmaceuticals, Inc.	PDCD-1 homing endonuclease variants
EP3895052A4 (en)	2018-12-14	2022-10-26	2seventy bio, Inc.	DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES
MX2021013588A (es)	2019-05-08	2022-02-11	Medigene Immunotherapies Gmbh	Células t genomodificadas.
US12613239B2 (en)	2019-05-10	2026-04-28	Institut Pasteur	Live imaging system to visualize the retro-transcribed viral DNA genome
US12109235B2 (en)	2019-06-21	2024-10-08	Kite Pharma, Inc.	TGF-beta receptors and methods of use
AU2020341454A1 (en)	2019-09-03	2022-03-10	Sana Biotechnology, Inc.	CD24-associated particles and related methods and uses thereof
JP7640538B2 (ja)	2019-10-08	2025-03-05	トラスティーズオブボストンカレッジ	複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
CA3160178A1 (en)	2019-11-05	2021-05-14	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
AU2021357520A1 (en)	2020-03-05	2022-09-29	Neotx Therapeutics Ltd.	Methods and compositions for treating cancer with immune cells
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
EP4127144A1 (en)	2020-03-31	2023-02-08	Sana Biotechnology, Inc.	Targeted lipid particles and compositions and uses thereof
US20230190871A1 (en)	2020-05-20	2023-06-22	Sana Biotechnology, Inc.	Methods and compositions for treatment of viral infections
CN117120085A (zh)	2020-07-15	2023-11-24	巴斯德研究所	Sars-cov-2免疫原性组合物、疫苗和方法
EP4501951A3 (en)	2020-08-25	2025-04-30	Kite Pharma, Inc.	T cells with improved functionality
US20230303665A1 (en)	2020-08-28	2023-09-28	Sana Biotechnology, Inc.	Modified anti-viral binding agents
WO2022058621A1 (en)	2020-09-21	2022-03-24	Theravectys	High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (en)	2020-10-16	2022-04-20	Institut Pasteur	Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
JP2023550309A (ja)	2020-11-04	2023-12-01	セルジーンコーポレーション	以前に抗がんアルキル化剤療法を受けた患者におけるｃａｒｔ細胞療法
EP4272002A1 (en)	2020-12-04	2023-11-08	Celgene Corporation	Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
KR20230124656A (ko)	2020-12-24	2023-08-25	카이트 파마 인코포레이티드	전립선암 키메라 항원 수용체
CA3204161A1 (en)	2021-01-11	2022-07-14	Jagesh Vijaykumar SHAH	Use of cd8-targeted viral vectors
US20250319173A1 (en)	2021-03-12	2025-10-16	Institut Pasteur	Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CA3216056A1 (en)	2021-04-16	2022-10-20	Kite Pharma, Inc.	Taci/bcma dual binding molecules
AU2022257093A1 (en)	2021-04-16	2023-11-02	Celgene Corporation	T cell therapy in patients who have had prior stem cell transplant
US12331315B2 (en)	2021-05-24	2025-06-17	Kite Pharma, Inc.	Chimeric antigen receptor
WO2022251712A1 (en)	2021-05-28	2022-12-01	Sana Biotechnology, Inc.	Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
CN117730100A (zh)	2021-06-08	2024-03-19	凯德药业股份有限公司	Gpc3结合分子
AU2022310862A1 (en)	2021-07-14	2024-02-01	Regeneron Pharmaceuticals, Inc.	Engineered t cell receptors fused to binding domains from antibodies
EP4373951A1 (en)	2021-07-19	2024-05-29	2seventy bio, Inc.	Vector manufacturing processes
WO2023009989A1 (en)	2021-07-26	2023-02-02	Kite Pharma, Inc.	Split chimeric antigen receptors and methods of use
US20240344083A1 (en)	2021-08-04	2024-10-17	Sana Biotechnology, Inc.	Use of cd4-targeted viral vectors
AR127745A1 (es)	2021-10-18	2024-02-28	Kite Pharma Inc	Dominios de señalización para receptores quiméricos de antígenos
US20250230511A1 (en)	2021-10-29	2025-07-17	Sana Biotechnology, Inc.	Methods and reagents for amplifying viral vector nucleic acid products
WO2023114949A1 (en)	2021-12-16	2023-06-22	Sana Biotechnology, Inc.	Methods and systems of particle production
US20250059239A1 (en)	2021-12-17	2025-02-20	Sana Biotechnology, Inc.	Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en)	2021-12-17	2023-06-22	Sana Biotechnology, Inc.	Modified paramyxoviridae attachment glycoproteins
WO2023133595A2 (en)	2022-01-10	2023-07-13	Sana Biotechnology, Inc.	Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4472646A1 (en)	2022-02-01	2024-12-11	Sana Biotechnology, Inc.	Cd3-targeted lentiviral vectors and uses thereof
WO2023150647A1 (en)	2022-02-02	2023-08-10	Sana Biotechnology, Inc.	Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en)	2022-04-01	2025-07-10	Sana Biotechnology, Inc.	Cytokine receptor agonist and viral vector combination therapies
IL316032A (en)	2022-04-08	2024-11-01	Regeneron Pharma	Multicomponent receptor and signaling complexes
US20250295771A1 (en)	2022-05-11	2025-09-25	Celgene Corporation	Methods and uses related to t cell therapy and production of same
IL317172A (en)	2022-05-26	2025-01-01	Regeneron Pharma	Lentiviral vector maintenance vehicles and uses thereof
US20260027145A1 (en)	2022-07-27	2026-01-29	Sana Biotechnology, Inc.	Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
US20260055146A1 (en)	2022-08-24	2026-02-26	Sana Biotechnology, Inc.	Delivery of heterologous proteins
WO2024064838A1 (en)	2022-09-21	2024-03-28	Sana Biotechnology, Inc.	Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
WO2024081820A1 (en)	2022-10-13	2024-04-18	Sana Biotechnology, Inc.	Viral particles targeting hematopoietic stem cells
TW202423456A (zh)	2022-10-21	2024-06-16	法商賽拉福柯蒂斯公司	表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
WO2024119157A1 (en)	2022-12-02	2024-06-06	Sana Biotechnology, Inc.	Lipid particles with cofusogens and methods of producing and using the same
WO2024220574A1 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220560A1 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220597A2 (en)	2023-04-18	2024-10-24	Sana Biotechnology, Inc.	Digital droplet based assay for detecting replication competent lentiviral vector
AU2024274792A1 (en)	2023-05-23	2025-10-23	Sana Biotechnology, Inc.	Tandem fusogens and related lipid particles
WO2025088552A1 (en)	2023-10-25	2025-05-01	Kanglin Biotech (Hangzhou) Co., Ltd.	Nucleic acid constructs and uses thereof
WO2025153530A1 (en)	2024-01-16	2025-07-24	Novo Nordisk A/S	Albumin-targeted endonucleases, compositions, and methods of use
WO2025184529A1 (en)	2024-03-01	2025-09-04	Sana Biotechnology, Inc.	Viral particles with fusogen display and related compositions and methods
WO2025240518A1 (en)	2024-05-14	2025-11-20	Dispatch Biotherapeutics, Inc.	Modified lentiviral transfer plasmids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69430646T2 (de) *	1993-02-17	2003-01-02	Wisconsin Alumni Research Foundation, Madison	Retroviren vom Typ "more-complex", die LTR von gemischtem Typ enthalten und deren Anwendungen
US6013516A (en) *	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
US6004799A (en) *	1996-03-05	1999-12-21	The Regents Of The University Of California	Recombinant live feline immunodeficiency virus and proviral DNA vaccines
WO1998039463A2 (en) *	1997-03-06	1998-09-11	Ueberla Klaus	Lentivirus based vector and vector system
WO1998046083A1 (en)	1997-04-17	1998-10-22	The Regents Of The University Of California	Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr)	1998-04-24	2002-08-02	Pasteur Institut	Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en)	1998-06-03	2009-11-24	Kappes John C	Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en)	1998-11-20	1999-01-13	Oxford Biomedica Ltd	Vector
EP2169073B1 (en) *	1999-10-11	2013-11-13	Institut Pasteur	Vector for the preparation of immunotherapeutical compositions
WO2001027304A2 (en)	1999-10-12	2001-04-19	Institut Pasteur	Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20030194392A1 (en)	2002-04-10	2003-10-16	Pierre Charneau	Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
US8158413B2 (en)	2005-10-17	2012-04-17	Institut Pasteur	Lentiviral vector-based vaccine
US8222029B2 (en)	2005-05-16	2012-07-17	Institut Pasteur	Lentiviral vector-based vaccine

1998
- 1998-04-24 FR FR9805197A patent/FR2777909B1/fr not_active Expired - Lifetime
1999
- 1999-04-23 AT AT99915829T patent/ATE553205T1/de active
- 1999-04-23 EP EP10172183.5A patent/EP2292778B1/fr not_active Expired - Lifetime
- 1999-04-23 ES ES10172183.5T patent/ES2607484T3/es not_active Expired - Lifetime
- 1999-04-23 JP JP2000546035A patent/JP4571306B2/ja not_active Expired - Lifetime
- 1999-04-23 WO PCT/FR1999/000974 patent/WO1999055892A1/fr not_active Ceased
- 1999-04-23 ES ES99915829T patent/ES2384553T3/es not_active Expired - Lifetime
- 1999-04-23 PT PT99915829T patent/PT1071804E/pt unknown
- 1999-04-23 CA CA2326719A patent/CA2326719C/fr not_active Expired - Lifetime
- 1999-04-23 DK DK99915829.8T patent/DK1071804T3/da active
- 1999-04-23 AU AU34272/99A patent/AU3427299A/en not_active Abandoned
- 1999-04-23 EP EP99915829A patent/EP1071804B1/fr not_active Expired - Lifetime
2000
- 2000-10-17 US US09/688,990 patent/US6682907B1/en not_active Expired - Lifetime
2003
- 2003-06-25 US US10/602,663 patent/US20060040347A1/en not_active Abandoned
2008
- 2008-05-28 US US12/153,959 patent/US7981671B2/en not_active Expired - Fee Related
2010
- 2010-06-10 US US12/813,375 patent/US8367068B2/en not_active Expired - Fee Related
2011
- 2011-09-21 US US13/238,133 patent/US8450087B2/en not_active Expired - Fee Related
- 2011-09-21 US US13/238,184 patent/US8460678B2/en not_active Expired - Fee Related
2012
- 2012-07-09 CY CY20121100608T patent/CY1112985T1/el unknown

Also Published As

Publication number	Publication date
EP2292778B1 (fr)	2016-09-14
US8460678B2 (en)	2013-06-11
ATE553205T1 (de)	2012-04-15
ES2607484T3 (es)	2017-03-31
HK1034283A1 (en)	2001-10-19
FR2777909A1 (fr)	1999-10-29
FR2777909B1 (fr)	2002-08-02
US6682907B1 (en)	2004-01-27
US20100221820A1 (en)	2010-09-02
EP1071804A1 (fr)	2001-01-31
CY1112985T1 (el)	2016-04-13
US20120095083A1 (en)	2012-04-19
EP1071804B1 (fr)	2012-04-11
US20120252114A1 (en)	2012-10-04
US20120252113A1 (en)	2012-10-04
CA2326719C (fr)	2011-04-12
ES2384553T3 (es)	2012-07-06
WO1999055892A1 (fr)	1999-11-04
PT1071804E (pt)	2012-06-26
JP4571306B2 (ja)	2010-10-27
JP2002512804A (ja)	2002-05-08
EP2292778A1 (fr)	2011-03-09
US8367068B2 (en)	2013-02-05
US20060040347A1 (en)	2006-02-23
AU3427299A (en)	1999-11-16
US7981671B2 (en)	2011-07-19
US8450087B2 (en)	2013-05-28
CA2326719A1 (fr)	1999-11-04

Publication	Publication Date	Title
ATE553205T1 (de)	2012-04-15	Verwendung von dns-sequenzen mit triplex-structur zum transfer von nukleotidsequenzen
Charneau et al.	1994	HIV-1 reverse transcription A termination step at the center of the genome
Shub et al.	1988	Structural conservation among three homologous introns of bacteriophage T4 and the group I introns of eukaryotes.
Berkhout et al.	2000	The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.
Platt	1994	Rho and RNA: models for recognition and response
Barat et al.	1991	Interaction of HIV-1 reverse transcriptase with a synthetic form of its replication primer, tRNALys, 3
Kleiman	2002	tRNALys3: The Primer tRNA for Reverse Transcription in HIV‐1
US6114109A (en)	2000-09-05	Viral (HIV) growth inhibition
Arts et al.	1996	Initiation of (-) strand DNA synthesis from tRNA (3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA (3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.
AU2020278864B2 (en)	2026-04-16	Single base substitution protein, and composition comprising same
Ling et al.	2002	The solitary long terminal repeats of ERV-9 endogenous retrovirus are conserved during primate evolution and possess enhancer activities in embryonic and hematopoietic cells
Rounseville et al.	1992	Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA
AU692163B2 (en)	1998-06-04	Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells
DK1792997T3 (da)	2012-01-30	Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
JP2019501882A5 (da)	2019-10-24
DK0544894T3 (da)	2002-04-22	Anvendelse af exo-prøve-nukleotider i genkloning
DK0403333T3 (da)	2000-03-20	Nukleotidsekvenser stammende fra genomet i retrovirus af typen HIV-1, HIV-2 og SIV og deres anvendelse, fortrinsvis til opf
TR200401186T4 (tr)	2004-07-21	Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
Ghosh	1992	Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat
Rezende et al.	1998	The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity
Tarrago‐Litvak et al.	1994	The reverse transcriptase of HIV‐1: from enzymology to therapeutic intervention
Weiss et al.	1992	Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA
Martínez-Salas et al.	1996	Identification of an essential region for internal initiation of translation in the aphthovirus internal ribosome entry site and implications for viral evolution
EP0578776A4 (en)	1995-04-12	INHIBITION OF A RETROVIRUS USING NON-ENCODING NUCLEIC ACIDS HYBRIDIZING ON ENCAPSIDATION SEQUENCES.
Churcher et al.	1995	The RNA element encoded by the trans-activation-responsive region of human immunodeficiency virus type 1 is functional when displaced downstream of the start of transcription.